In conclusion, this study establishes LNP‐delivered base editing the Agxt mutations as a curative strategy for PH1 in rat models, validates its efficacy in adult‐onset treatment, and defines critical therapeutic thresholds. The gene discussed is AGXT; the disease is primary hyperoxaluria type 1.